噁拉戈利
Elagolix (NBI-56418)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
1 mg 5 mg 10 mg
Product Availability
3-5days
Price
$100.00
Member price
Product Availability
3-5days
Price
$215.00
Member price
Product Availability
3-5days
Price
$338.00
Member price
Quantity
- +
Product Overview
Product Name Elagolix (NBI-56418)
CAS834153-87-6
FormulaC32H30F5N3O5
MW631.59
AppearanceWhite to off-white powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Security information
Product details

Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management. It inhibits GnRHR with a Kd of 54 pM. Elagolix was given FDA approval on July 23, 2018, to treat endometriosis-related moderate to severe pain. A short-acting GnRH antagonist, elagolix suppresses ovarian estrogen production in a dose-dependent manner, resulting in partial suppression at lower doses and complete suppression at higher doses. Because Elagolix is non-peptide and readily absorbed through the mouth, it is considered the leader of a new class of GnRH inhibitors known as second-generation inhibitors.

Related literature
Related
Sorry, no related items
History
Elagolix (NBI-56418)
S-(-)-Carbidopa | Carbidopa
(2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid; LY341495
Vantictumab (Anti-FZD)
BIX-01294 trihydrochloride | BIX01294 triHCl
Recombinant TEV Protease (rTEV)
Talabostat | Val-boroPro | PT100
Pranoprofen
Etoposide phosphate
Darolutamide | ODM-201 | BAY-1841788